FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis

Cryptococcal Meningitis Included in FDA Tropical Disease Priority Review Voucher Program SAN DIEGO, Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening inf... Biopharmaceuticals, FDA Amplyx Pharmaceuticals, APX001, cryptococcosis

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044747

Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news